Interstitial Lung Disease

Respiratory·MeSH: Lung Diseases, Interstitial

Prevalence

30.0 / 100K

19 drugs in development·16 companies·15 clinical trials

Drug Pipeline by Phase

Approved(9)

Drug	Company
etorel	GYRE THERAPEUTICS, INC. (GYRE)
nintedanib	EXELIXIS, INC. (EXEL)
nintedanib	X4 Pharmaceuticals, Inc (XFOR)
nintedanib	GYRE THERAPEUTICS, INC. (GYRE)
nintedanib	Aptinyx Inc. (APTX)
nintedanib	DR REDDYS LABORATORIES LTD (RDY)
nintedanib	NYMOX PHARMACEUTICAL CORP (NYMXF)
tyvaso dpi	MANNKIND CORP (MNKD)
YUTREPIA	Liquidia Corp (LQDA)

Phase 3(3)

Phase 2(4)

Drug	Company
INS1148	INSMED Inc (INSM)
L-menthol	Crinetics Pharmaceuticals, Inc. (CRNX)
mosliciguat	Roivant Sciences Ltd. (ROIV)
tx45	Tectonic Therapeutic, Inc. (TECX)

Phase 1(1)

Drug	Company
ace-1334	ACCELERON PHARMA INC (XLRN)

Phase 4(2)

Drug	Company
telitacicept	GH Research PLC (GHRS)
tocilizumab	GH Research PLC (GHRS)

BioSniper tracks 19 drugs in development for Interstitial Lung Disease across 16 companies.

There are 15 clinical trials targeting Interstitial Lung Disease tracked by BioSniper.

The estimated prevalence of Interstitial Lung Disease is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.